CKD BIO CORP. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23,600 KRW | -0.21% |
|
+1.29% | -1.05% |
| 2023 | CKD Bio Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
| 2023 | CKD Bio Corp.(KOSE:A063160) dropped from S&P Global BMI Index | CI |
| Sales 2021 | 142B 103M | Sales 2022 | 156B 113M | Capitalization | 131B 94.79M |
|---|---|---|---|---|---|
| Net income 2021 | -6.58B -4.77M | Net income 2022 | -16.7B -12.13M | EV / Sales 2021 | 2.36 x |
| Net Debt 2021 | 106B 76.84M | Net Debt 2022 | 126B 91.62M | EV / Sales 2022 | 1.65 x |
| P/E ratio 2021 |
-34.9
x | P/E ratio 2022 |
-7.82
x | Employees | 519 |
| Yield 2021 |
0.24% | Yield 2022 |
-
| Free-Float | 60.84% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.21% | ||
| 1 week | +1.29% | ||
| Current month | -1.46% | ||
| 1 month | -5.98% | ||
| 3 months | +4.89% | ||
| 6 months | +19.80% | ||
| Current year | -1.05% |
1 week
23 050.00
23 800.00
1 month
22 750.0025 400.00
Current year
21 900.0025 850.00
1 year
19 050.0027 850.00
3 years
19 050.0088 400.00
5 years
19 050.00119 000.00
10 years
11 619.05119 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jeong-Jin Lee
CEO | Chief Executive Officer | 59 | - |
Jin-Hyo Jung
BRD | Director/Board Member | 62 | 15-03-19 |
Han-Joon Kim
PRN | Corporate Officer/Principal | 63 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jang-Han Lee
PRN | Corporate Officer/Principal | 71 | - |
Jeong-Jin Lee
CEO | Chief Executive Officer | 59 | - |
Jin-Hyo Jung
BRD | Director/Board Member | 62 | 15-03-19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 23,600 | -0.21% | 7,801 |
| 24-04-23 | 23,650 | +0.85% | 4,449 |
| 24-04-22 | 23,450 | 0.00% | 3,511 |
| 24-04-19 | 23,450 | -1.68% | 10,302 |
| 24-04-18 | 23,850 | +2.36% | 3,905 |
End-of-day quote Korea S.E., April 23, 2024
More quotes
CKD Bio Corp. is a Korea-based company specialized in the manufacturing of pharmaceutical products. The Company mainly provides antibiotic ingredients, consisting of demethylchlortetracyclines (DMCTs) and rifampicins. It also provides immunosuppressive agents, including cyclosporin and tacrolimus; remedies for diabetes, such as acarbose, and potassium clavulanate used for beta-lactam inhibitors. The Company distributes its products within domestic market and to overseas markets, such as America, China, Europe, Africa, Southeast Asia, Latin America and the Middle East.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -1.05% | 94.52M | |
| +25.61% | 672B | |
| +25.87% | 570B | |
| -5.24% | 360B | |
| +16.49% | 321B | |
| +8.28% | 300B | |
| +7.09% | 217B | |
| -9.12% | 204B | |
| +5.01% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- A063160 Stock
